NUTX profile · all as-reported value updates
Nutex Health Inc. (NUTX) as-reported value updates
Descriptive filing record — not investment advice. This page compares two SEC XBRL-filed values for the same fiscal period. It does not state why the values differ and is not a rating, score, or recommendation. See Disclaimer.
Reported values for the same fiscal period can differ between filings for many routine reasons: re-presentation for discontinued operations, adoption of new accounting standards, reclassifications, changes in rounding precision, and amendments. This ledger records that the filed values differ; it does not and cannot determine why. Both filings are linked below so the reader can consult the source.
Ledger table figure
| Metric | FY | Earliest XBRL-filed value | Currently on file | Difference | Difference % | Label | Filing links | Notes |
|---|---|---|---|---|---|---|---|---|
| Stockholders' equity | 2018 | 1,233,019 | -1,497,353 | -2,730,372 | -182.35% | revised comparative figure | 0001607062-19-000163 0001607062-21-000074 | 3 filed observations examined for this concept and period. |
| Stockholders' equity | 2017 | 2,368,975 | -997,224 | -3,366,199 | -142.10% | revised comparative figure | 0001607062-18-000127 0001607062-20-000125 | 3 filed observations examined for this concept and period. |
| Net income | 2021 | -13,668,624 | 132,593,328 | 146,261,952 | +110.31% | revised comparative figure | 0001607062-22-000229 0001558370-24-004287 | 3 filed observations examined for this concept and period. |
| Net income | 2020 | -5,650,167 | 105,969,885 | 111,620,052 | +105.33% | revised comparative figure | 0001607062-21-000074 0001558370-23-002713 | 3 filed observations examined for this concept and period. |
| Operating income | 2021 | -9,018,075 | 170,264,898 | 179,282,973 | +105.30% | revised comparative figure | 0001607062-22-000229 0001558370-24-004287 | 3 filed observations examined for this concept and period. |
| Operating cash flow | 2021 | -6,703,530 | 173,432,486 | 180,136,016 | +103.87% | revised comparative figure | 0001607062-22-000229 0001558370-24-004287 | 3 filed observations examined for this concept and period. |
| Operating income | 2020 | -5,187,702 | 153,173,887 | 158,361,589 | +103.39% | revised comparative figure | 0001607062-21-000074 0001558370-23-002713 | 3 filed observations examined for this concept and period. |
| Operating cash flow | 2020 | -1,475,075 | 86,671,757 | 88,146,832 | +101.70% | revised comparative figure | 0001607062-21-000074 0001558370-23-002713 | 3 filed observations examined for this concept and period. |
| Capital expenditures | 2020 | 0.00 | 61,188,768 | 61,188,768 | +100.00% | revised comparative figure | 0001607062-21-000074 0001558370-23-002713 | 2 filed observations examined for this concept and period. |
| Gross profit | 2020 | 676,172 | 157,606,159 | 156,929,987 | +99.57% | revised comparative figure | 0001607062-21-000074 0001558370-23-002713 | 3 filed observations examined for this concept and period. |
| Revenue | 2020 | 1,585,952 | 274,029,061 | 272,443,109 | +99.42% | revised comparative figure | 0001607062-21-000074 0001558370-23-002713 | 3 filed observations examined for this concept and period. |
| Gross profit | 2021 | 4,146,738 | 179,280,958 | 175,134,220 | +97.69% | revised comparative figure | 0001607062-22-000229 0001558370-24-004287 | 3 filed observations examined for this concept and period. |
| Revenue | 2018 | 60,224 | 1,366,996 | 1,306,772 | +95.59% | revised comparative figure | 0001607062-19-000163 0001607062-20-000125 | 2 filed observations examined for this concept and period. |
| Liabilities | 2021 | 10,594,906 | 203,069,033 | 192,474,127 | +94.78% | revised comparative figure | 0001607062-22-000229 0001558370-23-002713 | 2 filed observations examined for this concept and period. |
| Revenue | 2021 | 18,793,783 | 331,531,311 | 312,737,528 | +94.33% | revised comparative figure | 0001607062-22-000229 0001558370-24-004287 | 3 filed observations examined for this concept and period. |
| Assets | 2018 | 2,618,466 | 449,428 | -2,169,038 | -82.84% | revised comparative figure | 0001607062-19-000163 0001607062-20-000125 | 2 filed observations examined for this concept and period. |
| Assets | 2021 | 85,733,528 | 394,650,043 | 308,916,515 | +78.28% | revised comparative figure | 0001607062-22-000229 0001558370-23-002713 | 2 filed observations examined for this concept and period. |
| Net income | 2018 | -2,814,245 | -950,129 | 1,864,116 | +66.24% | revised comparative figure | 0001607062-19-000163 0001607062-20-000125 | 2 filed observations examined for this concept and period. |
| Cash and cash equivalents | 2021 | 15,314,328 | 36,118,284 | 20,803,956 | +57.60% | revised comparative figure | 0001607062-22-000229 0001558370-23-002713 | 2 filed observations examined for this concept and period. |
| Gross profit | 2022 | 13,452,382 | 15,421,738 | 1,969,356 | +12.77% | revised comparative figure | 0001558370-23-002713 0001628280-25-052895 | 4 filed observations examined for this concept and period. |
| Stockholders' equity | 2024 | 146,344,749 | 132,439,000 | -13,905,749 | -9.50% | revised comparative figure | 0001479681-25-000006 0001628280-26-015168 | 3 filed observations examined for this concept and period. |
| Cash and cash equivalents | 2024 | 43,581,412 | 40,640,000 | -2,941,412 | -6.75% | revised comparative figure | 0001479681-25-000006 0001628280-26-015168 | 3 filed observations examined for this concept and period. |
| Liabilities | 2024 | 453,428,516 | 466,787,000 | 13,358,484 | +2.86% | revised comparative figure | 0001479681-25-000006 0001628280-26-015168 | 3 filed observations examined for this concept and period. |